About the Registry
OUR MISSION
At the heart of the COMPPASS Registry is a commitment to improving health outcomes for children affected by invasive Group B Streptococcus (iGBS). We focus on collecting and analyzing data related to neonatal iGBS to understand its long-term impacts and address the challenges faced by families. Through this work, we strive to create a world where every child and family affected by iGBS has access to the care, support, and resources they need.
​
OUR VISION
We envision a future where families no longer face the uncertainty of iGBS alone. By combining real-world data with cutting-edge research, the COMPPASS Registry aims to advance care, treatment, and prevention strategies globally, paving the way for better outcomes and brighter futures for children impacted by iGBS.​
OUR HISTORY
The COMPPASS Registry was born from a deep commitment to creating a global movement that unites families, healthcare professionals, and researchers. Recognizing the need for better understanding and support, we set out to build a platform where insights can be shared, challenges addressed, and collaborative efforts driven to create meaningful change.
WHY IT MATTERS
Families affected by iGBS often face unique challenges, from managing developmental delays to navigating complex healthcare systems. These experiences provide invaluable insights that can shape the future of care and research. By joining the COMPPASS Registry, families contribute directly to a growing body of knowledge that drives innovation, improves support systems, and ensures no family feels alone on their journey.
A HISTORICAL CONTEXT
Invasive Group B Streptococcus (iGBS) emerged as a significant public health concern in the mid-20th century, when it was identified as a leading cause of neonatal sepsis and meningitis. In the 1970s, research established the role of maternal colonization in transmitting the bacteria to newborns, paving the way for the development of intrapartum antibiotic prophylaxis (IAP) in the 1990s. While IAP has drastically reduced early-onset iGBS in high-income countries, challenges remain, including addressing late-onset disease and expanding prevention measures to low- and middle-income countries.
The iGBS COMPPASS Registry builds on this legacy by advancing research, improving patient outcomes, and guiding global efforts in iGBS management and prevention.